慢性乙型肝炎和肝硬化患者血浆miR-181a水平变化*

doi:10.3969/j.issn.1672-5069.2017.04.031

Abstract

Deng Xin, Wu Jian.. Plasma miR-181a levels in patients with chronic hepatitis B[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(4): 494-495.

[1] Brunetto MR,Cavallone D,Oliveri F,et al. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. Plos one,2014,9（10）:e110782.
[1] 麻树霖,陈征,刘晓峰,等.血清MicroRNA作为生物学标记物对肝硬化诊断及预后判断研究进展.实用肝脏病杂志,2016,19（5）:629-632.
[2] 樊丽萍,陈建杰,凌琪华,等. MicroRNA-122与肝脏疾病.实用肝脏病杂志,2013,15（1）:85-87.
[3] 许文剑.miRNA与肿瘤关系的研究进展.医学综述,2013,19（17）:3120-3123.
[4] Brunetto MR,Cavallone D,Oliveri F,et al. A serum microRNA signature is associated with the immune control of chronic hepatitis B virus infection. Plos one,2014,9（10）:e110782.
[5] 吴君.乙型肝炎病毒感染的综合性预防.世界华人消化杂志, 2006,14（12）:1135-1138.
[6] 徐怡,陈光明,宓现强,等. miRNA在肿瘤早期诊断中的价值及其检测技术进展.检验医学,2013,28（3）:248-251.
[7] Li L M,Hu ZB, Zhou ZX,et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res,2010,70（23）:9798-9807.
[8] Zhang G,Li Y,Zheng S,et al. Suppression of hepatitis B virus replication by microRNA-199a-3p and microRNA-210. Antiviral Res,2010,88（2）:169-175.
[9] Zhou J,Yu L,Gao X,et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 2011,29（36）:4781-4788.
[10] Brockhausen J,Tay SS,Grzelak CA,et al. miR-181a mediates TGF β induced hepatocyte EMT and is dysregulated in cirrhosis and hepatocellular cancer. Liver Int,2015,35（1）:240-253.
[11] Liu Y,Zhao JJ,Wang C,et al. Altered expression profiles of microRNAs in a stable hepatitis B virus-expressing cell line. Chin Med J,2009,122（1）:10-14.
[12] Chen Y,Shen A,Rider P J,et al. A liver-specific microRNA binds to a highly conserved RNA sequence of hepatitis B virus and negatively regulates viral gene expression and replication. FASEB J,2011,25（12）:4511-4521.
[13] He S,Zeng S,Zhou ZW,et al. Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients:a bioinformatic and clinical study and the therapeutic implication. Drug Design Develop Ther,2015,9:1103.
[14] Yang CC,Hung PS,Wang PW,et al. miR-181 as a putative biomarker for lymph node metastasis of oral squamous cell carcinoma. J Oral Pathol Med,2011,40（5）:397-404.
[15] Guo LJ,Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. Int J Mol Med,2012,30（3）:680-686.

Plasma miR-181a levels in patients with chronic hepatitis B

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[3]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[4]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[5]	Zhang Yafei, Ye Jun, Xie Qinxiu, et al. Difference in predicting efficacy of significant liver fibrosis by noninvasive liver fibrosis index in different hospitals [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 510-513.
[6]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[7]	Wang Ming, Zhang Shu, Li Ming, Wen Jun, Zheng Zhenjiang. Comparative study of serum and fecal HBV DNA in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 176-179.
[8]	Jiang Yi, Liu Bing. Comparison of clinical features and histopathological activity index between patients with chronic hepatitis B and chronic hepatitis C [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 188-191.
[9]	Hu Hulan, Zhu Mengfei, Shi Junping.. Non-alcoholic fatty liver disease with concurrent chronic hepatitis B: What’s the progress [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 149-152.
[10]	Wang Yaofeng.. Efficacy and safety of tenofovir in the treatment of patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 847-850.
[11]	Huang Chunming, Yang Zhan, Nie Yuqiang, et al.. Prediction of liver fibrosis by gamma-glutamyl-transpeptidase-to-platelet ratio in patients with chronic hepatitis B viral infection with normal serum transaminase levels [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 859-862.
[12]	Baoyan, Wang Yun, Xiang Xiaogang, et al.. Prognosis of patients with hepatocellular carcinoma and underlying hepatitis B An [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 924-927.
[13]	Zhou Zhiling, Yin Qian.. Forecasting hepatic activity index and liver fibrosis staging by serum golgiprotein-73 levels in individuals with chronic hepatitis B viral carriers [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 717-720.
[14]	Wang Fangfang, Zhang Guofan, Guo Chunxia, et al.. Clinical efficacy and safety of switching from entecavir to interferon-α in patients with hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 721-724.
[15]	Shi Luoming, Zhou Gengfa, Sun Donglin. Prediction of response in patients with low serum HBsAg level chronic hepatitis B receiving peginterferon-α-2a after nucleos(t)ide analogues treatment [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 565-568.